Loading…
Lobbying Spend
—
Filings
68
Firms Hired
4
Active Period
2016–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Lower Costs, More Cures Act of 2021
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Lower Costs, More Cures Act of 2021
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Lower Costs, More Cures Act of 2021
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: S. 2164
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Client expense: — · Firm income: $50,000
Matched citations: S.Con.Res. 14
Lower Costs, More Cures Act of 2021
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Lower Costs, More Cures Act of 2021
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Inflation Reduction Act of 2022
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Cures 2.0 and issues related to FDA. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Lower Costs, More Cures Act of 2021
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
Client expense: — · Firm income: $50,000
Matched citations: S. 2164
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2021 · third_quarter · Firm: THE NICKLES GROUP, LLC
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
Client expense: — · Firm income: $50,000
Matched citations: S.Con.Res. 14
Prescription Drug Pricing Reduction Act of 2019
2021 · third_quarter · Firm: Polsinelli PC
Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act. S. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based payment Issues related to value-based drug pricing and drug pricing in general
Client expense: — · Firm income: —
Matched citations: S. 2543
Lower Costs, More Cures Act of 2021
2021 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Lower Costs, More Cures Act of 2021
2021 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 19
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act. Monitored FY 2022 Budget Resolution.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Lower Costs, More Cures Act of 2021
2021 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2164
Prescription Drug Pricing Reduction Act of 2019
2021 · second_quarter · Firm: Polsinelli PC
Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act. S. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based payment Issues related to value-based drug pricing and drug pricing in general
Client expense: — · Firm income: $30,000
Matched citations: S. 2543
Prescription Drug Pricing Reduction Act of 2019
2021 · first_quarter · Firm: Polsinelli PC
Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act. S. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based payment Issues related to value-based drug pricing and drug pricing in general
Client expense: — · Firm income: $50,000
Matched citations: S. 2543
Consolidated Appropriations Act, 2021
2020 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
S. 2543 Prescription Drug Pricing Act and issues related to value based payment over time; H.R. 5882 Gene Therapy Payment Act; H.R. 3935, the Protecting Patients Transportation to Care Act; issues related to the Notice of Proposed rulemaking supporting VBP Arrangement; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021; monitored issues related to the Most Favored Nation (MFN) rule.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 133
Source: Senate LDA